Forest Laboratories and Cypress to launch fibromyalgia drug
Savella (milnacipran HCl), was approved by the FDA on January 14, 2009 and was originally expected to be available in March 2009. The companies submitted a minor post-approval
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.